NCT01702090View on ClinicalTrials.gov

Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
HIV-1
Interventions
DRUG

TMC114/ritonavir

TMC114 800 mg (two tablets) once daily coadministered with ritonavir 100 mg (one capsule) once daily within 30 minutes after completion of a meal, and in combination with other ARVs.

Trial Locations (1)

Unknown

Taipei

All Listed Sponsors
lead

Janssen-Cilag Ltd.

INDUSTRY

NCT01702090 - Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients | Biotech Hunter | Biotech Hunter